卫生署：“1+”审批机制11月起扩展至所有新药体现“好药港用”

阿斯达克财经10-25

卫生署今日(25日)表示，按照《行政长官2024年施政报告》公布的措施，“1+”审批机制将于今年11月1日起扩展至所有新药，包括疫苗及先进疗法制品，体现“好药港用”。扩展“1+”机制可吸引更多来自世界各地的新药来港注册，让病人有更多选择，并强化本地的药物审核能力和促进相关软硬件和人才发展，进一步迈向“第一层审批”。政府会以制度创新配合科技创新，发展香港成为国际医疗创新枢纽。根据《药剂业及毒药条例》...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2478624180?lang=zh_CN&edition=full","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240409110313882_s.jpg","is_english":false,"pubTime":"2024-10-25 13:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478624180","market":"sh","top_or_hot":-1,"title":"卫生署：“1+”审批机制11月起扩展至所有新药  体现“好药港用”","media":"阿斯达克财经","content":"<div>\n<p>卫生署今日(25日)表示，按照《行政长官2024年施政报告》公布的措施，“1+”审批机制将于今年11月1日起扩展至所有新药，包括疫苗及先进疗法制品，体现“好药港用”。扩展“1+”机制可吸引更多来自世界各地的新药来港注册，让病人有更多选择，并强化本地的药物审核能力和促进相关软硬件和人才发展，进一步迈向“第一层审批”。政府会以制度创新配合科技创新，发展香港成为国际医疗创新枢纽。根据《药剂业及毒药条例》...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1391169/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>卫生署：“1+”审批机制11月起扩展至所有新药  体现“好药港用”</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n卫生署：“1+”审批机制11月起扩展至所有新药  体现“好药港用”\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-25 13:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1391169/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>卫生署今日(25日)表示，按照《行政长官2024年施政报告》公布的措施，“1+”审批机制将于今年11月1日起扩展至所有新药，包括疫苗及先进疗法制品，体现“好药港用”。扩展“1+”机制可吸引更多来自世界各地的新药来港注册，让病人有更多选择，并强化本地的药物审核能力和促进相关软硬件和人才发展，进一步迈向“第一层审批”。政府会以制度创新配合科技创新，发展香港成为国际医疗创新枢纽。根据《药剂业及毒药条例》...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1391169/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0005HP3H50.USD","symbol_name":"GUINNESS CHINA \"C\" (USD) ACC","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1391169/latest-news/AAFN","article_id":"2478624180","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240409110313882_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478624180","pubTimestamp":1729834500,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"卫生署今日表示，按照《行政长官2024年施政报告》公布的措施，“1+”审批机制将于今年11月1日起扩展至所有新药，包括疫苗及先进疗法制品，体现“好药港用”。“1+”机制将于今年11月1日起扩展至适用于所有新药申请。卫生署已在有关网页公布扩展“1+”审批机制至所有新药的安排，并主动向持份者介绍关于“1+”机制的扩展及相关细节。首两款按“1+”机制获批治疗转移性结直肠癌的新药，已获纳入医管局药物名册的专用药物类别。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300760":"迈瑞医疗","603259":"药明康德","IE0005HP3H50.USD":"GUINNESS CHINA \"C\" (USD) ACC","LU2348773727.SGD":"Aberdeen Standard SICAV I - Asian Sustainable Development Equity A Acc SGD-H","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1997245177.USD":"安联神洲A股基金","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","IE0008368742.USD":"首域中国增长基金I Acc","LU2153592121.USD":"Aberdeen Standard SICAV I - Emerging Markets Sustainable Development Equity A Acc USD","01530":"三生制药","BK1207":"个人用品","LU0605514214.HKD":"FIDELITY CHINA CONSUMER \"A\" (HKD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","01801":"信达生物","BK1589":"北水核心资产","LU2153591404.USD":"Aberdeen Standard SICAV I - Asian Sustainable Development Equity A Acc USD","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","SGXZ81163826.USD":"UNITED CHINA A-SHARES INNOVATION \"A\" (USD) ACC","LU1720050803.USD":"安联全方位中国股票基金","BK1583":"高瓴概念","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0823426308.USD":"法巴中国股票基金","LU2348774022.SGD":"Aberdeen Standard SICAV I - Emerging Markets Sustainable Development Equity A Acc SGD-H","IE00B031J352.USD":"FSSA GREATER CHINA GROWTH \"I\" (USD) INC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","IE0031814852.USD":"FSSA GREATER CHINA GROWTH \"I\" (USD) ACC","LU0594300419.USD":"富达中国消费基金A","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","SGXZ49509284.SGD":"United China A Shares Innovation A Acc SGD","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","LU0594300179.USD":"FIDELITY CHINA CONSUMER \"A\" (USD) ACC","02367":"巨子生物","LU0823426480.USD":"法巴中国股票经典Dis","LU2424517915.HKD":"abrdn SICAV I -  ASIAN SDG EQUITY \"A\" (HKD) ACC","BK0216":"研究试验","06990":"科伦博泰生物-B","BK1593":"医美概念股","BK1161":"生物科技","LU1146622755.USD":"安本中国A股股票基金A Acc","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC"},"translate_title":"Department of Health: The \"1 +\" approval mechanism will be extended to all new drugs from November, reflecting \"good drugs for Hong Kong use\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300760":1,"603259":1,"01801":1,"02367":1,"06990":1,"01530":1},"content_text":"卫生署今日(25日)表示，按照《行政长官2024年施政报告》公布的措施，“1+”审批机制将于今年11月1日起扩展至所有新药，包括疫苗及先进疗法制品，体现“好药港用”。扩展“1+”机制可吸引更多来自世界各地的新药来港注册，让病人有更多选择，并强化本地的药物审核能力和促进相关软硬件和人才发展，进一步迈向“第一层审批”。政府会以制度创新配合科技创新，发展香港成为国际医疗创新枢纽。根据《药剂业及毒药条例》(第138章)，药剂制品必须符合安全、效能及素质标准，并获得香港药剂业及毒药管理局批准注册，方可在香港销售或分销。去年11月1日起生效的“1+”机制，用以治疗严重或罕见疾病的新药注册申请，在符合本地临床数据支持等要求，并经本地专家认可新药的适用范围后，加上提交一个(而非过往要求的两个)参考药物监管机构的注册许可，便可以在香港申请注册。“1+”机制将于今年11月1日起扩展至适用于所有新药申请。卫生署已在有关网页公布扩展“1+”审批机制至所有新药的安排，并主动向持份者(包括相关药剂业联会和药剂制品注册证明书持有人)介绍关于“1+”机制的扩展及相关细节。详情可见卫生署药物办公室网页。卫生署亦会在2025年第一季为“1+”新药注册申请前提供会面咨询服务，提升处理相关申请的效率。自“1+”机制生效以来，卫生署已收到80多间药厂超过260个查询，当中包括海外及内地药厂。共有五款新药按此机制获批准注册，包括两款治疗转移性结直肠癌症、一款用于阵发性睡眠性血红蛋白尿症，以及两款用作治疗副甲状腺癌患者和某类原发性副甲状腺功能亢进症患者的高血钙症的新药申请，为病人带来治疗新希望。首两款按“1+”机制获批治疗转移性结直肠癌的新药，已获纳入医管局药物名册的专用药物类别。在特定的临床应用下获处方该两款药物的病人，药费会获得大幅资助，即病人只需支付标准费用，大大减轻其负担。医管局会鼓励药物生产商或供应商，就有持续需要使用的未经注册药物申请本地注册，并继续因应“1+”机制与卫生署紧密联系。相关内容《大行》招银国际：关注创新品种医保机遇  看好药明康德(603259.SH)、百济神州(BGNE.US)、信达生物(01801.HK)、科伦博泰(06990.HK)、巨子生物(02367.HK)、三生制药(01530.HK)和迈瑞医疗(300760.SZ)《施政报告》亦宣布其他加快改革药物审批制度的措施，包括在2025年上半年提出“香港药械监管中心”成立时间表和迈向“第一层审批”路线图，以及制订药物研发支援策略和措施。(da/a)AASTOCKS新闻","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2478624180"}

卫生署：“1+”审批机制11月起扩展至所有新药 体现“好药港用”

精彩评论

卫生署：“1+”审批机制11月起扩展至所有新药体现“好药港用”